Basic information
- Standard SMILES
COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1- InChIKey
GLBJJMFZWDBELO-UHFFFAOYSA-N- Molecular formula
- C19H18N4O2
- Average molar mass
- 334.4 g/mol
- Monoisotopic mass
- 334.14297582
Overview
Pimobendan is a member of benzimidazoles and a pyridazinone. It has a role as a vasodilator agent, a cardiotonic drug and an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor.
Names & identifiers
- Preferred name
- Pimobendan
- IUPAC
- 3-[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one
- English name
- l-Pimobendan
- Molecular formula
- C19H18N4O2
- Molecular weight
- 334.37
Names & synonyms
Show more names
Database identifiers
- CAS
118428-37-8、118428-38-9、74150-27-9- PubChem CID
- 4823
- DTXSID
DTXSID8048280- ChEMBL
CHEMBL24646- ChEBI
CHEBI:32003- UNII
- 34AP3BBP9T、613JXV89SU、9HTU209Z0N
- EC Number
- 640-420-7
- Nikkaji
- J34.390K
Properties
Computed structural properties
- XLogP
- 2.7
- Topological polar surface area
- 79.4 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 3
- Heavy atoms
- 25
- Formal charge
- 0
- Complexity
- 530
Experimental & physicochemical properties
Animal Drugs
FDA approved animal drugs -> Active ingredient
Pharmaceuticals -> UK Veterinary Medicines Directorate List
Physicochemical properties
- Boiling point
- 471.18 °C · 471.18°C (rough estimate)
- Density
- 1.2421 · 1.2421 (rough estimate)
- refractive index
- 1.662 · 1.6620 (estimate)
- pka
- 10.21 · 10.21±0.10(Predicted)
- FDA UNII
- 9 HTU209Z0N · 9HTU209Z0N
Safety & regulation
GHS classification
GHS Classification
Danger
H301 (20%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P261, P264, P270, P271, P273, P280, P301+P316, P301+P317, P304+P340, P317, P318, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 10 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Chemistry & industry
Pharmacology
MeSH Pharmacological Classification
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.
Drugs used to cause dilation of the blood vessels.
Applications
Uses(-)-Pimobedan is an isomer of pimobedan. It has the property of stereoselective partitioning or distribution into erythrocytes. The clearance of (-)-pimobedan from erythrocytes is significantly lower than that of (+)-pimobedan, which is entirely due to its stereoselective distribution into erythrocytes. This stereoselective property of (-)-pimobedan may explain the phenomenon previously reported that it produces a 1.5-fold greater contractile force than the (+)-isomer in detergent-treated myocardial specimens of guinea pigs and dogs. These properties suggest that (-)-pimobedan may have unique advantages in terms of in vivo distribution and pharmacological action, which may have important implications for its clinical use.
Suppliers1 total
Additional notes
DefinitionChEBI: Pimobendan is a pyridazinone and a member of benzimidazoles. It has a role as a cardiotonic drug, a vasodilator agent and an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor.
Related reactions
No reaction records under the current filter.
Linked notes
Loading…